Lunit Inc.

Lunit Inc.

KKRX:328130
15,820.00
KRW
+1,120.00
(+7.62%)
-846.75EPS
850.94BMarket Cap
Mar 24Next Earn
Lunit Inc.
KRX:328130
(Korea Stock Exchange)

Recent

price

15,820.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
0.42
4.12
87.68
235.29
290.35
456.09
878.25
1,334.42
1,434.05
Revenue per Share
-170.6
-976.11
-5,134.29
-2,611.09
-819.13
-669.18
-1,340.49
-760.72
-869.76
Basic EPS, GAAP
-140.53
-216.45
-1,079.1
-1,186.46
-1,193.21
-692.21
-1,173.12
-1,040.33
-866.19
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-310.23
-1,388.31
-3,080.53
48.05
1,232
3,829.92
2,628.9
2,194.26
4,458.59
Book Value per Share
-311.38
-1,389.88
-3,086.26
37.49
1,203.79
3,802.72
-1,806.85
-2,255.55
512.19
Tangible Book Value per Share
48
48
16
28
48
55
62
62
64
Basic Weighted Avg Shares
20
198
1,430
6,639
13,866
25,080
54,180
83,129
91,818
Sales/Revenue/Turnover
-33,690.6
-5,846.12
-1,464.04
-688.36
-365.51
-168.39
-125.44
-99.99
-76.42
Operating Margin (%)
219
375
1,321
2,066
3,040
3,772
7,972
10,307
10,706
Depreciation Expense
-8,210
-46,972
-83,739
-73,676
-39,118
-36,798
-82,695
-47,390
-55,688
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-41,048.81
-23,675.02
-5,855.73
-1,109.74
-282.12
-146.72
-152.63
-57.01
-60.65
Profit Margin (%)
-6,846
-58,711
-131,232
1,993
58,604
217,624
-140,531
-156,592
20,369
Working Capital
- -
39
313
77
17,838
17,111
15,762
14,311
13,375
LT Debt
-13,156
-58,875
-130,638
2,038
68,910
235,110
162,735
137,433
331,642
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-110.27
-24.21
-41.57
-31.58
-23.52
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
97,273
134,117
95,585
LT Borrowings
- -
- -
- -
LT Finance Leases
14,311
13,782
13,375
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
59
74
Market Capitalization
1,203,591
956,139
850,937

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,620
77,323
217,163
Cash, Cash Equivalents & STI
20,888
41,049
182,142
Accounts Receivable, Net
21,802
23,370
22,374
Inventories
124
185
113
Total Current Liabilities
212,212
243,654
196,795
Payables & Accruals
- -
- -
- -
ST Debt
97,273
134,117
95,585
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
675.04%
-15.55%
Free Cash Flow
- -
41.38%
-10.45%
Net Income, GAAP
- -
3.44%
-42.69%
Sales/Revenue/Turnover
- -
144.69%
53.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,140
12,230
16,770
20,039
54,180
2025
19,203
17,875
19,576
26,476
83,129
2026
23,952
21,814
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-183.75
226.77
-190.76
-1,186.29
-1,340.49
2025
30.39
-280.53
290.29
-518.53
-760.72
2026
-304.13
-324.76
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Lunit Inc. (KRX: 328130) develops and provides artificial intelligence-powered software solutions for cancer screening, diagnostics, and therapeutics. The company offers Lunit INSIGHT CXR for chest X-ray analysis; Lunit INSIGHT MMG for 2D mammography; Lunit INSIGHT DBT for digital breast tomosynthesis; Lunit SCOPE for biomarker analysis including immune phenotyping, PD-L1 quantification, and genotype prediction; and Lunit CXR Triage for emergency department chest X-ray prioritization. These FDA-cleared solutions support medical imaging, pathology, and precision oncology across over 4,800 institutions in more than 55 countries. Founded in 2013 and headquartered in Seoul, South Korea, Lunit operates globally with offices in Boston, Massachusetts, and Amsterdam, Netherlands, targeting healthcare providers, radiologists, and biopharma partners. In 2024, Lunit completed its US$193 million acquisition of Volpara Health Technologies, enhancing breast cancer screening capabilities and expanding U.S. market presence to over 200 imaging centers by mid-2025, surpassing 1 million mammograms analyzed. Recent strategic collaborations include a November 2025 partnership with Labcorp for AI-powered digital pathology; an alliance with AstraZeneca on Lunit SCOPE Genotype Predictor for NSCLC mutation analysis; and supply agreements with GE Healthcare, Philips, and Akumin for 3D breast imaging solutions, driving record H1 2025 revenue of KRW 37.1 billion.